Diagnosis and treatment of primary cutaneous T-cell lymphomas;Diagnóstico y tratamiento de los linfomas cutáneos de células T primarios

Actas Dermo-Sifiliograficas

Volumn 95, Issue 8, 2004, Pages 473-490

  Gallardo, Fernando ^a   Pujol, Ramón María ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Cutaneous lymphoma; Diagnosis; Treatment

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BEXAROTENE; CARMUSTINE; CD2 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; CD79A ANTIGEN; CD8 ANTIGEN; CHLORMETHINE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; GRANZYME B; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LEUKOSIALIN; PREDNISONE; PROTEIN BCL 6; RETINOID; UNINDEXED DRUG; VINBLASTINE;

APOPTOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL EXAMINATION; CLINICAL FEATURE; CUTANEOUS T CELL LYMPHOMA; HUMAN; IMMUNOHISTOCHEMISTRY; PROGNOSIS; PUVA; REVIEW; SKIN CARCINOGENESIS; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT PLANNING; VIRUS CARCINOGENESIS;

EID: 7944223830     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(04)76864-7     Document Type: Review

References (81)

1. Willemze R, Kerl H, Sterry W, Berti E, et al. EORTC Classification for Primary Cutaneous Lymphoma: a proposal from the cutaneous lymphoma study group of the European, Organization for Research and Treatment of Cancer. Blood 1997;90:354-71.
2. Jaffe E, Harris N, Steun H, Vardiman J. The Whorld Health Organization classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues. Lyon: LARC Press, 2001.
3. Slater D. The new World Health Organizaton classification of haematopoietic and lymphoid tumours: a dermatopathological perspective. Br J Dermatol 2002;147:633-9.
4. Russell-Jones R. Whorld Health Organization classification of hematopoietic and lymphoid tissues: implications for dermatology. J Am Acad Dermatol 2003;48:93-102.
5. Willemze R, Meijer C. EORTC Classification for Primary Cutaneous Lymphoma. The best guide to good clinical management. Am J Dermatopathol 1999;21:265-73.
6. Gómez S, Pérez N. Micosis fungoide y síndrome de Sézary. Actas Dermosifiliogr 2001;92:193-206.
7. Fung M, Murphy M, Hoss D, et al. Practical evaluation and management of cutaneous lymphoma. J Am Acad Dermatol 2002;46:325-57.
8. Lorincz AL. Cutaneous T-cell lymphoma (mycosis fungoides). Lancet 1996;347:871-6.
9. MacKie RM, Turbitt ML. A case of pagetoid reticulosis bearing the T cytotoxic suppressor surface marker on the lymphoid infiltrate: further evidence that pagetoid reticulosis is not a variant of mycosis fungoides. Br J Dermatol 1984;110:89-94.
10. Ko J-W, Seong J-Y, Suh K-S, Kim S-T. Pityriasis lichenoides-like mycosis fungoides in children. Br J Dermatol 2000;142:347-52.
11. LeBoit PE. Variants of mycosis fungoides and related cutaneous T-cell lymphomas. Semin Diagn Pathol 1991;8:73-81.
12. Pujol RM, Gallardo F, Llistosella E, et al. Invisible mycosis fungoides: a diagnostic challenge. J Am Acad Dermatol 2000;42:324-8.
13. Santucci M, Biggeri A, Feller AC, Burg G. Accuracy, concordance, and reproducibility of histologic diagnosis in cutaneous T-cell lymphoma: an EORTC cutaneous lymphoma project group study. Arch Dermatol 2000;136:497-502.
14. Gomez S, Fresno MF, Raya C, et al. Transformacion de la micosis fungoide/sindrome de Sézary a linfoma de células grandes. Actas Dermosifiliogr 2001;92:391-6.
15. Murphy M, Fullen D, Carlson JA. CD7 paraffin reactive antibody: loss of expression in benign and malignant cutaneous lymphocytic infiltrates [abstract]. J Cutan Pathol 2000;27:566.
16. Bergman R, Faclieru D, Sahar D, et al. Immunophenotyping and T-cell receptor gamma gene rearrangement analysis as an adjunct to the histopathologic diagnosis of mycosis fungoides. J Am Acad Dermatol 1998;39:554-9.
17. Murphy M, Signoretti S, Kadin ME, Loda M. Detection of TCR-gene rearrangements in early mycosis fungoides by non-radioactive PCR-SSCP. J Cutan Pathol 2000;27:228-34.
18. Navas IC, Ortiz-Romero PL, Villuendas R, et al. p16INK4a gene alterations are frequent in lesions of mycosis fungoides. Am J Pathol 2000;156:1565-72.
19. Whittaker SJ, Marsden JR, Spittle M, Russell Jones R. Joint British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003;149:1095-107.
20. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999;40:418-25.
21. Van Doom R, Van Haselen CW, Van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136:504-10.
22. Fraser-Andrews E, Woolford AJ, Russell-Jones R, Seed PT, Whittaker SJ. Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol 2000;114:117-21.
23. Dmitrovsky E, Matthews MJ, Bunn PA, et al. Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis. J Clin Oncol 1987;5:208-15.
24. Kaye FJ, Bunn PA, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:1784-90.
25. Zackheim HS. Cutaneous T-cell lymphoma: update of treatment. Dermatology 1999;199:102-5.
26. Martin FJ, Ortega M, Camacho F. Fototerapia UVB en micosis fungoide. Actas Dermosifiliogr 2000;91:98-100.
27. Hofer A, Cerroni L, Kerl H, Wolf P. Narrowband (311-nm) UV-B therapy for small-plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol 1999;135:1377-80.
28. Plettenberg H, Stege H, Megahed M, et al. Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1999;41:47-50.
29. Herrmann JJ, Roenigk HH, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995;33:234-42.
30. Hoppe RT, Abel EA, Deneau DG, Price NM. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol 1987;5:1796-803.
31. Zackheim HS. Topical carmustine (BCNU) for patch/plaque mycosis fungoides. Semin Dermatol 1994;13:202-6.
32. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Arch Dermatol 1998;134:949-54.
33. Breneman D, Duvic M, Kuzel TM, et al. Phase I and II trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002;138:325-32.
34. Hoppe RT. Total skin electron beam therapy in the management of mycosis fungoides. Front Radiat Ther Oncol 1991;25:80-9.
35. Wilson LD, Jones GW, Kim D, et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol 2000;43:54-60.
36. Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999;86:1368-76.
37. Foss FM, Ihde DC, Breneman DL, et al. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 1992;10:1907-13.
38. Trautinger F, Schwarzmeier J. Low-dose 2-chlorodeoxyadenosine for the treatment of mycosis fungoides. Arch Dermatol 1999;135:1279-80.
39. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma:experience in 44 patients. J Clin Oncol 2000;18:2603-6.
40. Wollina U, Graefe T, Karte K. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 2000;42:40-6.
41. Zic JA, Stricklin GP, Greer JP, et al. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996;35:935-45.
42. Stadler R, Otte H-G, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998;92:3578-81.
43. Ross C, Tingsgaard P, Jorgensen H, Vejlsgaard GL. Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol 1993;51:63-72.
44. Jumbou O, N'Guyen JM, Tessier MH, Legoux B, Dreno B. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol 1999;140:427-31.
45. Duvic M, Hymes K, Heald P, et al. Bexarotene Worldwide Study Group: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-71.
46. Marolleau JP, Baccard M, Flageul B, et al. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995;131:574-9.
47. Saleh MN, LeMaistre CF, Kuzel TM, et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998;39:63-73.
48. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III mal of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88.
49. Knox S, Hoppe RT, Maloney D, et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996;87:893-9.
50. Berger CL, Longley BJ, Imaeda S, Christensen I, Heald P, Edelson RL. Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor. Int J Cancer 1998;76:304-11.
51. Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999;94:902-8.
52. Duvic M, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996;34:1022-9.
53. Guitar J, Wickless SC, Oyama Y, et al. Long-term remission after allogenic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 2002;138:1359-65.
54. Marti RM, Pujol RM, Servitje O, et al. Sezary syndrome and related variants of classic cutaneous T-cell lymphoma. A descriptive and prognostic clinicopathologic study of 29 cases. Leuk Lymphoma 2002:1-11.
55. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood 1996;88:2385-409.
56. Gómez E, Ortiz P, Vanaclocha F, et al. Factores clínicos y analiticos de progresión y supervivencia en linfomas cutáneos de células T (micosis fungoide/sindrome de Sézary). Actas Dermosifiliogr 2003;94:356-67.
57. Coors EA, Von den Driesch P. Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy. Br J Dermatol 2000;143:127-31.
58. Zackheim HS, Epstein EH. Low-dose methotrexate for the Sezary syndrome. J Am Acad Dermatol 1989;21:757-62.
59. Fraser-Andrews E, Seed P, Whittaker S, Russell-Jones R. Extracorporeal photopheresis in Sezary syndrome. Arch Dermatol 1998;134:1001-5.
60. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:4267-72.
61. Gillian A, Wood G. Primary cutaneous other than Mycosis Fungoide. Semin Oncol 1999;26:290-306.
62. Siegel RS, Pandolfino T, Guitart J, et al. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000;18:2908-25.
63. Beljaards RC, Kaudewitz P, Berti E, et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European multicenter study of 47 patients. Cancer 1993;71:2097-104.
64. Bekkenk MW, Geelen FA, Van Voorst Vader PC, et al. Primary and secondary cutaneous CD30+ lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of patients and guidelines for diagnosis and treatment. Blood 2000;95:3653-61.
65. el-Azhary RA, Gibson LE, Kurtin PJ, et al. Lymphomatoid papulosis: A clinical and histopathologic review of 53 cases with leukocyte immunophenotyping, DNA flow cytometry, and T-cell receptor rearrangement studies. J Am Acad Dermatol 1994;30:210-8.
66. Cabanillas F, Armitage J, Pugh Wg, Weisenburger D, Duvic M. Lymphomatoid papulosis: A T-cell discrasis with a propensity to transform into malignant lymphoma. Ann Intern Med 1995;122:210-7.
67. Wood GS, Crooks CF, Uluer AZ. Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin. J Invest Dermatol 1995;105:51-55.
68. Drews R, Samel A, Kadin ME. Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin. Semin Cutan Med Surg 2000;19:109-17.
69. Natkunam Y, Warnke RA, Haghighi B, et al. Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical, and molecular analyses of seven cases. J Cutan Pathol 2000;27:392-9.
70. DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME. The t(2,5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996;87:3437-41.
71. Bekkenk M, Vermeer M, Jansen P, et al. Peripheral T-cell lymphomas unspecified presenting in die skin: analysis of pronostic factors in a group of 82 patients. Blood 2003;102:2213-19.
72. Friedmann D, Wechsler J, Delfau M-H, Esteve E, Farcet JP, de Muret A, et al. Primary cutaneous pleomorphic small T-cell lymphoma: a review of 11 cases. Arch Dermatol 1995;131:1009-15.
73. Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/Natural Killer Cell Cutaneous Lymphomas. Report of the EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003;97:610-27.
74. Marzano AV, Berti E, Paulli M, Caputo R. Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma. Arch Dermatol 2000;136:889-96.
75. Wang C-YE, Su WPD, Kurtin PJ. Subcutaneous panniculitic T-cell lymphoma. Int J Dermatol 1996;35:1-8.
76. El Shabrawi-Caelen L, Cerroni L, Kerl H. The clinicopathologic spectrum of cytotoxic lymphomas of the skin. Semin Cutan Med Surg 2000;19:118-23.
77. Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas: a distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999;155:483-92.
78. Savoia P, Novelli MT, Quaglino P, et al. CD56-positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous disease. Br J Dermatol 1997;137:966-71.
79. Petrella T, Dalac S, Maynadie M, et al. CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Am J Surg Pathol 1999;23:13746.
80. Natkunam Y, Smoller BR, Zehnder JL, Dorfman RF, Warnke RA. Aggressive cutaneous NK and NK-like T-cell lymphomas: clinicopathologic, immunohistochemical, and molecular analyses of 12 cases. Am J Surg Pathol 1999;23:571-81.
81. Chan JKC, Ng CS, Ngan KC, Hui PK, Lo STH, Lau WH. Angiocentric T-cell lymphoma of the skin: an aggressive lymphoma distinct from mycosis fungoides. Am J Surg Pathol 1988;12:861-76.